Navigation Links
Ascenta Therapeutics Highlights Multiple Data Presentations at,Upcoming AACR Annual Meeting

SAN DIEGO--(BUSINESS WIRE)--Apr 13, 2007 - Ascenta Therapeutics, Inc. announced today that its small molecule portfolio of apoptosis-triggering compounds will be featured in three oral presentations and several poster presentations at next week's 2007 Annual Meeting of the American Association for Cancer Research (AACR), to be held in Los Angeles, California April 14-18, 2007.

Ascenta's MDM2 program has been selected for presentation at the "High Impact Late-Breaking Research 1" session on Tuesday, April 17 (Hall A at 3:30pm) and will be presented by Dajun Yang, MD, PhD, Senior Vice President of Research at Ascenta Therapeutics and General Manager of Ascenta's R&D Subsidiary in Shanghai, China. The MDM2 program will also be featured in a talk on Saturday, April 14 (Petree D at 4:15pm) by University of Michigan's Professor Shaomeng Wang, PhD, a co-founder of Ascenta.

Preclinical studies of AT-101, Ascenta's clinical stage, oral pan-Bcl-2 inhibitor, will be featured in an oral presentation by Dr. Yang on Wednesday, April 18 and in several poster presentations authored by Ascenta personnel and collaborating investigators. In a collaboration with scientists at Human Genome Sciences, Inc., studies of HGSI's TRAIL receptor agonist monoclonal antibodies in combination with Ascenta's small molecule XIAP inhibitors, will be presented in a poster session on Tuesday, April 17 (1pm-5pm). The full schedule of presentations featuring Ascenta's technology is as follows: -0-

Date      Time      Title                              Presenter,

                                                        Collaborator

--------- --------- ---------------------------------- --------------

Saturday  4:15pm    Potent, specific, non-peptidic     Shaomeng Wang,

April 14             small molecule inhibitors of the   PhD, U.

                     Human MDM2-p53 interaction as a    Michigan

                     new class of anticancer therapy

--------- --------- --------
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:1/23/2015)... , Jan. 23, 2015  A new analysis of ... D 2015 enrollment data shows that 81 percent of ... access and extra discounts at certain pharmacies. The findings ... "Preferred pharmacy plans are now the foundation of Medicare ...
(Date:1/23/2015)... , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( ... of directors of Advaxis, Inc. ("Advaxis" or the "Company") ... has breached its fiduciary duties to shareholders. ... an investing website reporting that Advaxis had misrepresented the ...
(Date:1/23/2015)... 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that the ... Lixte,s lead compound, LB‑100, is being conducted, has been expanded ... Kovach , M.D., the founder and President of Lixte, said ... a single site. Accrual of patients, however, was slower than ...
Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... UBM Canon,s publishing group,s leading brands European Medical Device ... and Diagnostic Industry ( MD+DI ) and ... Applications " on May 24, 2011.  Devoted to developments in ... offered the opportunity to learn from and interact directly with ...
... Medicines can cure disease, relieve symptoms, and help you ... of damage if taken incorrectly, when not needed, or ... Studies estimate that up to 50 ... Learn how FDA—through its Safe Use Initiative—is ...
Cached Medicine Technology:UBM Canon's Virtual Event Dedicated to Developments in Materials for Medical Applications 2UBM Canon's Virtual Event Dedicated to Developments in Materials for Medical Applications 3
(Date:1/22/2015)... NJ (PRWEB) January 22, 2015 Joan ... and keynote speaker at the upcoming 32nd Annual ... ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , shares ... would have gone undetected if she had not followed ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Yesterday, ... Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were honored ... leadership in advancing biotechnology, biomedical science, medical device ... Olsen each received the “2014 Life Sciences Champion” ...
(Date:1/22/2015)... January 22, 2015 IsoComforter, Inc. has introduced ... with patented IsoTube design to treat specific body parts and ... most progressive and easy to use patented cold therapy machine ... sports related orthopedic and muscle injuries. IsoComforter has become ...
(Date:1/22/2015)... Payday lending practices in four southern states worsen ... to the states that permit them, according to a ... Race and Wealth. , While they generate hundreds of ... the same time substantially depress economic activity, according to ...
(Date:1/22/2015)... As interest in the value of spiritual support as ... Rev. Eric J. Hall , president and CEO of the ... the keynote speaker on January 27 at an international summit ... The conference, “Hope and Resilience: Innovative and Interdisciplinary Spiritual Care,” ...
Breaking Medicine News(10 mins):Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
... years ago, the first Ronald McDonald House(R) opened its ... home" for families with seriously ill children. Today, McDonald,s(R) ... celebration to commemorate this important milestone and their long-standing ... , , "For 35 years, local McDonald,s franchisees ...
... For more than 30 years, consumers have benefited from the ... effects of the sun, including sun burn, premature skin aging, ... efficacy of sunscreen products have been thoroughly studied and tested ... is an extensive body of credible scientific research that demonstrates ...
... scientists, patients and members of the biotech industry from around ... unique research center on muscular dystrophy -- the Senator Paul ... , Established last year and based at Boston Biomedical Research ... Center and the only center in the world to focus ...
... Discovery may help explain why disease runs in families, , ... to inherited testicular germ-cell cancer has been identified by scientists ... contributes to our understanding of why testicular germ-cell cancer appears ... said in an agency news release. "The findings may also ...
... published in the July issue of The Journal ... (PET) scans in mice can be used to determine ... working as intended. Researchers successfully used PET and a ... with aggressive breast cancerin breast cancer cells before and ...
... NEW BRUNSWICK, N.J. and DUBLIN, July 2 Johnson & ... (NYSE: ELN ) today announced a definitive agreement ... assets and rights of Elan related to its Alzheimer,s Immunotherapy ... addition, Johnson & Johnson, through its affiliate, will invest $1 ...
Cached Medicine News:Health News:Ronald McDonald House Charities(R) (RMHC(R)) and McDonald's(R) Seek Inspiring Stories Through New 'Share.Give.Hope.' Campaign 2Health News:Ronald McDonald House Charities(R) (RMHC(R)) and McDonald's(R) Seek Inspiring Stories Through New 'Share.Give.Hope.' Campaign 3Health News:Statement by John Bailey, Chief Scientist The Personal Care Products Council, Response to EWG's 2009 Sunscreen Report 2Health News:Statement by John Bailey, Chief Scientist The Personal Care Products Council, Response to EWG's 2009 Sunscreen Report 3Health News:Statement by John Bailey, Chief Scientist The Personal Care Products Council, Response to EWG's 2009 Sunscreen Report 4Health News:Statement by John Bailey, Chief Scientist The Personal Care Products Council, Response to EWG's 2009 Sunscreen Report 5Health News:Successful Beginning for Wellstone Muscular Dystrophy Center at Boston Biomedical Research Institute 2Health News:Another Genetic Link to Testicular Cancer Is Found 2Health News:Study shows PET can measure effectiveness of novel breast cancer treatment 2Health News:Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity Investment 2Health News:Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity Investment 3Health News:Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity Investment 4Health News:Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity Investment 5
... Performance beyond your investment., ,The Centiva/5 Critical ... and time demands of the critical care environment. ... in mind combining a compact size with high ... up valuable space around the patients bed and ...
... Although other treatments for ,ED (e.g. ... used today, ,Vacuum Therapy is ... and their physicians ,because of the very ... should be used as a daily ,exercise ...
... is combining a lightweight mesh material with the ... hernia plug which stands for a high patient ... material is included in Premilene Mesh LP Self-Forming ... for a softer and less bulky Plug Premilene ...
... a mesh plug to treat large or ... hernias and femoralhernias. The self-expanding plug perfectly ... completely. Premilene Mesh Self-Forming Plug is a ... Mesh. The plug corresponds with all properties ...
Medicine Products: